



VISIONARY

Targeting a brighter future for IgAN patients.

A TRIAL OF SIBEPRENIMAB FOR
ADULTS WITH IgA NEPHROPATHY (IgAN)



Purpose: To study the effectiveness and safety of sibeprenlimab, an investigational drug for the treatment of IgAN (NCT05248646)¹



~470 participants
will be enrolled¹



Multicenter: ~300 global
sites in ~32 countries¹



ENROLLING NOW


To find out more information on the trial, email the study team at visionary@otsuka-us.com

What is IgAN? (Berger's disease)



Loss of
kidney
function

- IgA is a type of antibody that normally helps your body fight infection^{2,3}
- In IgAN, an abnormal type of IgA is produced, which the body will consider foreign and attack^{3,4}
- This leads to the formation of antibody clumps (complexes) in the kidney, causing damage^{3,4}



What is sibeprenlimab (sib-eh-pren-li-mab)?

- APRIL is a protein that likely plays a key role in the formation of IgA. Patients with higher levels of APRIL may produce higher levels of abnormal IgA⁵⁻⁷
- Sibeprenlimab is a monoclonal antibody designed to block the activity of APRIL⁵
- Early studies have shown that sibeprenlimab can bind to APRIL, blocking its activity and reducing the production of abnormal IgA⁵
- Blocking the activity of APRIL may prevent further kidney damage in patients with IgAN⁵

Sibeprenlimab is an investigational drug in clinical studies; its effectiveness and safety have not been established

What does the VISIONARY trial involve?

Efficacy endpoint: To assess whether sibeprenlimab is effective at preventing further kidney damage using a measure called the urine protein to creatine ratio (uPCR)¹



APRIL, A Proliferation-Inducing Ligand; IgA, immunoglobulin A; IgAN, immunoglobulin A nephropathy; OLE, open-label extension; SC, subcutaneous.

1. Otsuka Data on File, 2022. 2. He J-W et al. *Theranostics*. 2020;10:11462–11478. 3. IgA Nephropathy. National Institute of Diabetes and Digestive and Kidney Diseases. www.niddk.nih.gov/health-information/kidney-disease/iga-nephropathy. Accessed January 17, 2022.

4. Wyatt RJ and Julian BA. *N Engl J Med*. 2013;368:2402–2414. 5. Myette JR et al. *Kidney Int*. 2019;96:104–116.

6. Sallustio F et al. *Nephrol Dial Transplant*. 2021;36:452–464. 7. Han SS et al. *J Am Soc Nephrol*. 2016;27:3430–3439.